As Flu Season Approaches, Quidel Looks To Avoid Prior Pitfalls
This article was originally published in The Gray Sheet
Executive Summary
Rapid diagnostics maker Quidel is tweaking its business strategy to smooth out its balance sheet based on lessons learned from unpredictable flu seasons and this year's outbreak of the novel H1N1 strain
You may also be interested in...
Quidel Moves Beyond Point-Of-Care Focus With Diagnostic Hybrids Buy
Point-of-care-testing firm Quidel hopes to greatly expand its hospital and reference laboratory customer base, and become less reliant on flu season revenues, with its $130 million acquisition of Diagnostic Hybrids
Quidel Moves Beyond Point-Of-Care Focus With Diagnostic Hybrids Buy
Point-of-care-testing firm Quidel hopes to greatly expand its hospital and reference laboratory customer base, and become less reliant on flu season revenues, with its $130 million acquisition of Diagnostic Hybrids
Feds Seeking A Few Good Tests, And Masks, For Flu Season
With an especially challenging flu season expected this year, government officials are scrambling to evaluate the tools they have available to monitor, diagnose and limit spread of the virus